Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 412 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR How to Plan a ‘Safecation’ August 17, 2020 £82,000 of Donations Pour in for Mom with Incurable Cancer to... April 10, 2019 Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead... November 26, 2020 How to Spot Suspicious Herb and Supplement Claims During Cancer June 29, 2021 Load more HOT NEWS Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers Merging the Histologic and Molecular Data Into an Integrated Score Significantly... New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers Apple Season is Here!
